TorreyPines Therapeutics, Inc. and Eisai Co., Ltd. have extended their exclusive collaboration agreement that began in February 2005. This collaboration focuses on the discovery of novel, small molecules to treat Alzheimer’s disease (AD). It is TorreyPines’ second discovery collaboration with Eisai. In a separate series of agreements, dating back to 2001, the two companies are collaborating in a genetics program to discover AD targets using whole-genome family-based association scree...